| 11/05/2026 12:29 PM | FMR LLC (315066) Filed by Zevra Therapeutics (1434647) Subject | Form SCHEDULE 13G/A | |
| 11/03/2026 4:16 PM | Zevra Therapeutics (1434647) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
| 11/03/2026 3:08 PM | Zevra Therapeutics (1434647) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 10/13/2026 3:24 PM | McFarlane Neil F. (1681098) Reporting Zevra Therapeutics (1434647) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 10/13/2026 7:22 AM | McFarlane Neil F. (1681098) Reporting Zevra Therapeutics (1434647) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 08/17/2026 3:32 PM | Thompson Rahsaan (1788524) Reporting Zevra Therapeutics (1434647) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 08/14/2026 3:31 PM | Thompson Rahsaan (1788524) Reporting Zevra Therapeutics (1434647) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 08/14/2026 10:06 AM | Woodline Partners LP (1784547) Filed by Zevra Therapeutics (1434647) Subject | Form SCHEDULE 13G/A | |
| 08/12/2026 3:16 PM | Watton Corey Michael (1975404) Reporting Zevra Therapeutics (1434647) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 08/06/2026 9:48 AM | FMR LLC (315066) Filed by Zevra Therapeutics (1434647) Subject | Form SCHEDULE 13G/A | |
| 08/05/2026 4:19 PM | Zevra Therapeutics (1434647) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
Get the Latest News and Ratings for ZVRA and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Zevra Therapeutics and its competitors with MarketBeat's FREE daily newsletter.
|
| 07/31/2026 9:51 AM | VANGUARD CAPITAL MANAGEMENT LLC (2100119) Filed by Zevra Therapeutics (1434647) Subject | Form SCHEDULE 13G | |
| 07/08/2026 3:01 PM | Bode John B (1612084) Reporting Zevra Therapeutics (1434647) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/23/2026 3:16 PM | Thompson Rahsaan (1788524) Reporting Zevra Therapeutics (1434647) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/18/2026 3:15 PM | Shih Alvin (1610064) Reporting Zevra Therapeutics (1434647) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/18/2026 3:15 PM | Anderson Thomas (1612903) Reporting Zevra Therapeutics (1434647) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/18/2026 3:15 PM | Calder Douglas W (1510445) Reporting Zevra Therapeutics (1434647) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/18/2026 3:16 PM | Watton Corey Michael (1975404) Reporting Zevra Therapeutics (1434647) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/18/2026 3:16 PM | Secor Alicia (1584516) Reporting Zevra Therapeutics (1434647) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/18/2026 3:16 PM | FAVORITO TAMARA A (1288232) Reporting Zevra Therapeutics (1434647) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/05/2026 3:19 PM | Zevra Therapeutics (1434647) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 05/29/2026 3:16 PM | Sangiovanni Timothy J. (1698328) Reporting Zevra Therapeutics (1434647) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/13/2026 3:32 PM | Thompson Rahsaan (1788524) Reporting Zevra Therapeutics (1434647) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/11/2026 3:34 PM | Thompson Rahsaan (1788524) Reporting Zevra Therapeutics (1434647) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/06/2026 4:14 PM | Zevra Therapeutics (1434647) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
| 05/06/2026 3:05 PM | Zevra Therapeutics (1434647) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 05/06/2026 10:43 AM | FMR LLC (315066) Filed by Zevra Therapeutics (1434647) Subject | Form SCHEDULE 13G | |
| 04/20/2026 8:00 AM | Zevra Therapeutics (1434647) Filer | Form DEF 14A | |
| 04/06/2026 8:01 AM | Zevra Therapeutics (1434647) Filer | Form PRE 14A | |
| 03/27/2026 1:15 PM | VANGUARD GROUP INC (102909) Filed by Zevra Therapeutics (1434647) Subject | Form SCHEDULE 13G/A | |
| 03/26/2026 7:27 AM | Bode John B (1612084) Reporting Zevra Therapeutics (1434647) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 03/19/2026 3:14 PM | Renz Justin A (1466562) Reporting Zevra Therapeutics (1434647) Issuer | Form 3 Initial statement of beneficial ownership of securities | |
| 03/19/2026 3:15 PM | Renz Justin A (1466562) Reporting Zevra Therapeutics (1434647) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 03/16/2026 6:31 AM | Zevra Therapeutics (1434647) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 03/09/2026 3:23 PM | Zevra Therapeutics (1434647) Filer | Form 10-K Annual report pursuant to Section 13 or 15(d) | |
| 03/09/2026 3:27 PM | Zevra Therapeutics (1434647) Filer | Form S-8 Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
| 02/04/2026 3:27 PM | Schafer Joshua (1945557) Reporting Zevra Therapeutics (1434647) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/04/2026 3:27 PM | Sangiovanni Timothy J. (1698328) Reporting Zevra Therapeutics (1434647) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/30/2026 3:20 PM | Clifton R. LaDuane (1488774) Reporting Zevra Therapeutics (1434647) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 01/30/2026 3:21 PM | Sangiovanni Timothy J. (1698328) Reporting Zevra Therapeutics (1434647) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 01/07/2026 3:18 PM | Clifton R. LaDuane (1488774) Reporting Zevra Therapeutics (1434647) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
Pentagon magnet restrictions take effect January 1, 2027 (Ad) A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It would build and operate a rare earth processing facility on an active military base, with the Army receiving first right to production.
The timing matters. New Pentagon restrictions on certain Chinese-origin rare earth magnets take effect January 1, 2027, while China controls more than 90% of global rare earth processing.
The company's mine-to-magnet platform spans feedstock agreements, processing facilities, metallization technology, and downstream manufacturing, with initial commercial output targeted for 2027. Read the full breakdown of the proposed Army rare earth agreement and the company behind it. |
| 12/17/2025 3:15 PM | Zevra Therapeutics (1434647) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 12/02/2025 6:34 AM | Zevra Therapeutics (1434647) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |